Longitudinal stability of HyperSightTM-CBCT based radiomic features in patients with CT guided adaptive SBRT for prostate cancer

Abstract

Abstract CT-guided adaptive radiotherapy (aRT) based on HyperSightTM-CBCT provides high-quality imaging, allowing quantitative radiomic feature analysis as a monitoring tool. This study comprehensively evaluates the stability of radiomic features, as potential imaging biomarkers, in pelvic structures of prostate cancer patients treated with adaptive stereotactic body radiation therapy (SBRT). Between December 2023 and July 2024, 32 patients with localized prostate cancer underwent adaptive SBRT at the Ethos® linear accelerator (Varian, Siemens Healthineers) with HyperSight-CBCT imaging. Longitudinal stability was assessed by intraclass correlation coefficient (ICC) over five fractions of aRT for target structures and non-hollow organs at risk. In pooled organs at risk, 93.0% of features showed very high stability (ICC > 0.9) compared to 67.4% in pooled target structures, indicating significantly lower stability for target structures (p = 0.00009129). Second-order features demonstrated greater stability than conventional and shape-based features (p = 0.0433, p = 0.0252). Fraction number significantly affected longitudinal prostate feature variability (p = 0.0135). This study comprehensively analyzed HyperSight-CBCT imaging to evaluate longitudinal stability of radiomic features during adaptive SBRT for prostate cancer. The trends observed will provide a framework for future CT-guided aRT studies, facilitating quantitative imaging analysis of radiological biomarkers for clinical translation and improving personalized treatment.